|
WO2021081315A1
|
|
Compounds and methods for the treatment of cryptosporidiosis
|
|
WO2021077000A1
|
|
Engineered muscle targeting compositions
|
|
WO2021072328A1
|
|
Methods and compositions for prime editing rna
|
|
US2021102197A1
|
|
Designing sensitive, specific, and optimally active binding molecules for diagnostics and therapeutics
|
|
US2021100774A1
|
|
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
WO2021062410A2
|
|
Programmable polynucleotide editors for enhanced homologous recombination
|
|
WO2021055855A1
|
|
Compositions and methods for delivering cargo to a target cell
|
|
WO2021055874A1
|
|
Novel type vi crispr enzymes and systems
|
|
WO2021050974A1
|
|
Engineered adeno-associated virus capsids
|
|
WO2021050700A1
|
|
Cyclooxygenase-2 inhibitors and uses thereof
|
|
WO2021050521A1
|
|
Compositions, methods and uses for free fatty acid screening of cells at scale
|
|
US2021071255A1
|
|
Methods for identification of genes and genetic variants for complex phenotypes using single cell atlases and uses of the genes and variants thereof
|
|
WO2021046257A1
|
|
Crispr effector system based multiplex cancer diagnostics
|
|
WO2021046027A1
|
|
Rapid prediction of drug responsiveness
|
|
WO2021041922A1
|
|
Crispr-associated mu transposase systems
|
|
US2021047694A1
|
|
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
WO2021030666A1
|
|
Base editing by transglycosylation
|
|
US2021024655A1
|
|
Target recognition motifs and uses thereof
|
|
US2021050116A1
|
|
Health data aggregation and outbreak modeling
|
|
WO2021011524A1
|
|
Heterologous ribosome generation, assessment and compositions thereof
|
